Medical Tai Chi Exercise Healing in Treating mCRC Patients

Sponsor
The First Affiliated Hospital with Nanjing Medical University (Other)
Overall Status
Recruiting
CT.gov ID
NCT06104267
Collaborator
SIR RUNRUN Hospital (Other)
30
1
1
16
1.9

Study Details

Study Description

Brief Summary

As a traditional martial art in China, Tai Chi Chuan has excellent health benefits along with its combat function.Studies have shown that Tai Chi as an exercise prescription can significantly reduce the incidence of cancer, but the complexity of Tai Chi Chuan routines, poor disease targeting, and the lack of traditional internal mental and physical training method limit the healing of tumours and other diseases. For this reason, we have established the Medical Tai Chi Exercise Healing System(MTCEH), which integrates Tai Chi exercise, traditional Chinese internal mental and physical training method, rehabilitation medicine and sports medicine methods, on the basis of evidence-based medicine and with the aim of targeting different tumour treatments. With the characteristics of easily learning, internal and external training, and individualised treatment of tumours, this series of routines effectively combines traditional oriental Tai Chi martial arts with tumour treatment, which opens up a beautiful and mysterious oriental healing journey for integrative medicine.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: 7-Form of Medical Tai Chi Exercise Healing for Colon cancer patients
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
A Single-Arm, Prospective, Exploratory Study to Evaluate Feasibility and Effect of Medical Tai Chi Exercise Healing in Treating mCRC Patients
Actual Study Start Date :
Sep 1, 2023
Anticipated Primary Completion Date :
Sep 1, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Medical Tai Chi Exercise Group

Behavioral: 7-Form of Medical Tai Chi Exercise Healing for Colon cancer patients
The programme is based on the "7-Form of Medical Tai Chi Exercise Healing for Colon cancer patients" that lasted 60 minutes three times a week for eight weeks and is led by a Tai Chi instructor with more than 5 years of teaching experience. Each session included a warm-up, movement instruction, breathing techniques, and relaxation. To ensure that each participant is proficient in Tai Chi, they will take at least 2 sessions of 60-minute Tai Chi training before the start of the intervention, until they are able to perform all Tai Chi movements correctly and successfully, and record a video to be used in software for practice at home. The enrolled patients, Tai Chi instructors and relevant staff of the subject group set up a WeChat group, and the enrolled patients, outside of the prescribed practice time each week, can practice at home or outdoors by themselves. They can send the video of the practice to the WeChat group.

Outcome Measures

Primary Outcome Measures

  1. Adherence rates [post 8-week intervention]

    The adherence rates will be measured by the number of tai chi sessions performed divided by the total possible tai chi sessions

Secondary Outcome Measures

  1. the Brief Fatigue Inventory (BFI) [post 8-week intervention]

  2. the Pittsburgh Sleep Quality Index (PSQI) [post 8-week intervention]

  3. EORTC - Quality of Life [post 8-week intervention]

  4. self-rating anxiety scale(SAS) [post 8-week intervention]

  5. self-rating depression scale(SDS) [post 8-week intervention]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Histological or cytological documentation of adenocarcinoma of the colon or rectum.

  2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.

  3. Life expectancy of at least 6 months.

  4. Adequate bone marrow, liver, cardiac and renal function as assessed by the laboratory required by protocol(ALT/AST≤2.5×UNL or ≤5×UNL with liver metastasis,TBIL≤2.5×UNL,Cr≤1.5×UNL,WBC≥3×109/L,NE≥1.5×109/L,PLT≥80×109/L,Hb≥90g/L,PT-I NR/APTT <1.5UNL; LVEF≥ 50%).

  5. Subjects must complete the treatment and follow-up on schedule according to the research plan.

Exclusion Criteria:
  1. Previous or concurrent cancer that is distinct in primary site or histology from colorectal cancer EXCEPT for curatively treated cervical cancer in situ, non-melanoma skin cancer and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invades lamina propria)].

  2. Any serious or unstable medical condition、mental illness or known active alcohol or drug abuse or dependence.

  3. Unhealed surgical wounds and intolerance

  4. Extreme fatigue, anemia (<80 g/L) or dystaxia

  5. toxicity grade ≥III in chemoradiotherapy or targeted therapy (NCI-CTCAE 5.0), or severe intolerance

  6. exercise contraindications for patients with cardiovascular diseases or pulmonary diseases (referring to the Chinese Guideline for Cardiac Rehabilitation and Secondary Prevention [edition 2018] and Evidence-based Practice Guidelines for Clinical Rehabilitation of Chronic obstructive Pulmonary Disease [edition 2021]); uncontrolled unstable angina, diastolic dysfunction grade IV, uncontrolled severe arrhythmia, uncontrolled hypertension;

  7. high fever, serious infection, dyscrasia, multiple organ failure, or incapability to cooperate

  8. thrombosis in the active phase

  9. For female subjects: they should be surgical sterilized, postmenopausal patients, or agree to use a medically approved contraceptive method during the study treatment period and within 6 months after the end of the study treatment period; The serum or urine pregnancy test must be negative within 7 days before enrollment and must be non lactating. Male subjects: patients who agree to use a medically approved contraceptive method during the study treatment period and within 6 months after the end of the study treatment period.

  10. other conditions confirmed by the multidisciplinary cancer rehabilitation team.

Contacts and Locations

Locations

Site City State Country Postal Code
1 The First Affiliated Hospital with Nanjing Medical University Nanjing Jiangsu China 210029

Sponsors and Collaborators

  • The First Affiliated Hospital with Nanjing Medical University
  • SIR RUNRUN Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
The First Affiliated Hospital with Nanjing Medical University
ClinicalTrials.gov Identifier:
NCT06104267
Other Study ID Numbers:
  • KEEP-G 10
First Posted:
Oct 27, 2023
Last Update Posted:
Oct 27, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 27, 2023